Welcome to UMass Medical School Institutional Review Board

If you plan to conduct research involving human subjects, the research study must be reviewed and approved by the UMass Institutional Review Board before the study begins. Constituted as the Committee for the Protection of Human Subjects in Research, the UMass IRB serves as IRB of record for all human research conducted by UMass faculty and investigators at the Medical School or at associated research locations, including the campuses of UMass Memorial Medical Center and the member hospitals of UMass Memorial Health Care.

Detailed instructions on how to submit a research study to the IRB can be found in the Investigator’s Manual. Additional help is always available at the IRB Office at 508-856-4261 or email: IRB@umassmed.edu. We look forward to assisting you!

News & Announcements

News Updates:

2/4/2016:  Good Clinical Practice training will become a requirement for all investigators and staff involved in clinical trials, as defined by the NIH. Beginning May 1, 2016, GCP training will be required to support all new clinical trial IRB submissions. Training for investigators and staff submitting clinical trial continuing reviews will be required as of May 1, 2017.

  • Click Here to see the Memo
  • Click Here to See the "Good Clinical Practice (GCP) Training at UMMS" Brochure

2/3/2016: Minor revisions to ICF template & HIPAA Waiver

Informed Consent: Removed “that is not eligible for billing to your medical insurance” from the research injury language section for industry sponsored trials. HIPAA Waiver of Authorization: Updated the contact information in the footer. 

**When preparing an IRB submission, please be sure to visit the website to ensure that you are using the most up-to-date template(s) and/or forms**

1/6/2016: The University of Massachusetts Medical School’s Human Research Protection Program has been awarded full accreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).

9/1/2015: Effective September 1, 2015, submissions to the IRB that indicate the use of infectious agents, synthetic nucleic acids or radiation will be required to provide documentation that the protocol and consent has been reviewed and approved by IBC and/or RSC prior to IRB review. Click on the link for details IBC/RSC Review

Federalwide Assurance:
FWA#00004009
Expiration Date:
12/29/2020

IORG#0000160

IRB Registration #:
IRB 1: IRB00000269
IRB 2: IRB00000270

Statement of Compliance

▴ Back To Top
Section Menu To Top